Skip to content

solution injectable en ampoule

DRUG11 trials

Sponsors

Centre Hospitalier Bethune Beuvry, Centre Hospitalier Universitaire De Nantes, Assistance Publique Hopitaux De Paris, Centre Medico Chirurgical Ambroise Pare Hartmann, CHRU De Nancy

Conditions

Acute Myeloid LeukemiaAlzheimer DiseaseCardiorespiratory arrest at birth in full-term newbornsKnee arthroscopyOut-of-hospital cardiac arrest.Patients in ICU with invasive mechanical ventilation and HSV throat reactivation with 1 or no organ failures.Post-operative pain after surgerySickle cell disease

Phase 1

Phase 2

Phase 3

Preemptive Treament with acyclovir in intubated and mechanically ventilated patients with Herpes simplex virus oropharyngeal reactivation and one or less organ failure (PTH2)
RecruitingCTIS2023-505510-26-00
Assistance Publique Hopitaux De ParisPatients in ICU with invasive mechanical ventilation and HSV throat reactivation with 1 or no organ failures.
Start: 2024-06-19Target: 246Updated: 2026-01-07
TOCIACS : Efficacy and safety of Tocilizumab for acute chest syndrome treatment in paediatric and adult patients with sickle cell disease
RecruitingCTIS2023-505109-17-00
Assistance Publique Hopitaux De ParisSickle cell disease
Start: 2025-08-27Target: 130Updated: 2025-12-17
Impact of low dose epinephrine in the management of out-of-hospital cardiac arrest on neurological outcome: A multicenter randomized and double-blind trial (Low-EPI Study)
Not yet recruitingCTIS2023-505349-26-00
CHRU De NancyOut-of-hospital cardiac arrest.
Target: 4336Updated: 2025-10-08
Efficacy of intravenous dexamethasone in prolonging the duration of spinal anesthesia with chloroprocaine in knee arthroscopy.
Not yet recruitingCTIS2023-505247-39-00
Centre Medico Chirurgical Ambroise Pare HartmannKnee arthroscopy
Target: 60Updated: 2026-04-08
ECSIP : Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial
Not yet recruitingCTIS2025-524976-40-00
Centre Hospital Region Metz Thionvillepatients with influenza-induced acute hypoxemic respiratory failure
Target: 544Updated: 2026-06-23
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG-2
Not yet recruitingCTIS2026-525759-96-00
Centre Hospitalier Universitaire De ToulouseAcute Myeloid Leukemia
Target: 1290Updated: 2026-10-23

Phase 4

Related Papers